Comprehensive Tumor Profiling

Modern medical oncology goes towards more pathway focused apporaches as targeted panels are not enough to inform about driver and passanger mutations. Moreover, drug prescription based biomarker tests are not economic in both tissue, cost and time wise. That is why using the most extensive tools for tumor profiling can change the whole disaese outcome and future complications especially in advanced patients.

By utilizing next-generation sequencing (NGS) technologies, oncologists can obtain a comprehensive analysis of a patient’s tumor DNA, RNA, and proteome. This allows for a more personalized approach to treatment, as the specific mutations and pathways driving the tumor can be targeted with greater precision. Additionally, NGS testing can identify potential drug resistance mechanisms, which can inform treatment decisions and prevent unnecessary exposure to ineffective therapies. While NGS testing may initially come with a higher upfront cost, it can ultimately lead to cost savings by avoiding futile treatments and improving patient outcomes. As the field of oncology continues to evolve, it is clear that a more holistic approach to tumor profiling is necessary to provide the best possible care for
cancer patients.